For example, the addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), or cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), was found to increase survival rates in patients with ovarian cancer in chemotherapy (9, 10). The gene discussed is EGFR; the disease is ovarian cancer.